Article in Medicina (Kaunas, Lithuania), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors.
Erkam KocaaslanDepartment of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul 34899, Turkey.ORCID 0000-0002-8994-2904
Ali Kaan GürenDepartment of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul 34899, Turkey.ORCID 0000-0002-3562-5006
Fırat AkagündüzDepartment of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul 34899, Turkey.ORCID 0000-0001-7969-9464
Ahmet DemirelDepartment of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul 34899, Turkey.
Mustafa Alperen TunçDepartment of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul 34899, Turkey.ORCID 0000-0002-1537-3032
Burak PaçacıDepartment of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul 34899, Turkey.
Yeşim AğyolDepartment of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul 34899, Turkey.
Pınar ErelDepartment of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul 34899, Turkey.
Abdüssamed ÇelebiDepartment of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul 34899, Turkey.ORCID 0000-0002-6922-1018
Selver IşıkDepartment of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul 34899, Turkey.ORCID 0000-0002-2726-1740
Ezgi ÇobanDepartment of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul 34899, Turkey.
Nazım Can DemircanDepartment of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul 34899, Turkey.
Salih ÖzgüvenDepartment of Nuclear Medicine, Marmara University Pendik Training and Research Hospital, Istanbul 34899, Turkey.
Zeynep Ceren Balaban GençDepartment of Nuclear Medicine, Marmara University Pendik Training and Research Hospital, Istanbul 34899, Turkey.
Nargiz MajidovaDepartment of Medical Oncology, VM Medical Park Maltepe Hospital, Istanbul 34843, Turkey.ORCID 0000-0002-2575-5819
Nadiye SeverDepartment of Medical Oncology, Haydarpaşa Numune Training and Research Hospital, Istanbul 34668, Turkey.ORCID 0000-0001-7312-3827
Murat SarıDepartment of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul 34899, Turkey.ORCID 0000-0003-0596-1559
Osman KöstekDepartment of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul 34899, Turkey.
İbrahim Vedat BayoğluDepartment of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul 34899, Turkey.ORCID 0000-0002-0481-1084
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Prognostic Value of Treatment-Related Body Composition Changes in Metastatic NSCLC Receiving Nivolumab. · full record | Socratic